Comparison · NCT02927067-sae
Valganciclovir 900 mg BID vs Maribavir 400 mg BID: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Valganciclovir 900 mg BID vs Maribavir 400 mg BID: serious adverse events. Trial comparisons, record NCT02927067-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02927067-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.347 | 0.293 | 0.405 | wilson | |
| Risk in group 2 | 0.322 | 0.27 | 0.38 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0244 | -0.0545 | 0.103 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.08 | 0.849 | 1.36 | log | |
| Odds ratio, group 1 over group 2 | 1.12 | 0.782 | 1.59 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Valganciclovir 900 mg BID than on Maribavir 400 mg BID | 41 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Valganciclovir 900 mg BID | Participants received 900 mg of valganciclovir along with a placebo matched to maribavir, BID orally for 8 weeks. Valganciclovir dose was allowed to be adjusted to 450 mg BID or 450 mg QD based on renal function impairment assessed at baseline or development of neutropenia during the study. | 95 | 274 | EG000 |
| Group 2 | Maribavir 400 mg BID | Participants received 400 mg of maribavir along with a placebo matched to valganciclovir, BID orally for 8 weeks. | 88 | 273 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
All-cause mortality: From start of study drug up to end of the study (up to Week 20); Serious and Other Adverse Events: From the start of the study drug to 7 days after the last dose of study treatment (up to approximately Week 9)
Source ClinicalTrials.gov
Trial
- Title
- A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants
- NCT number
- NCT02927067
- Phases
- PHASE3
- Conditions
- Cytomegalovirus (CMV)
- Interventions
- Maribavir, Valganciclovir, Placebo
- Lead sponsor
- Shire
- Results first posted
- 2023-03-03
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02927067?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02927067-sae